{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T07:29:57.781302+00:00","company":{"ticker":"ADCT","cik":1771910,"company_name":"ADC Therapeutics SA"},"pagination":{"limit":100,"returned":16,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"shareholder_vote","fact_key":"0ab40d6d138120574e96ba7d805eb8674632a067","cik":1771910,"ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2026-06-02T20:01:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-01","outcome":"passed","proposal_text":"Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company’s capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as t","proposal_type":"charter_amendment","results":[{"broker_non_votes":"0","subject":"#12a","votes_abstain":"0","votes_against":"0","votes_for":"0","votes_withheld":null},{"broker_non_votes":"0","subject":"#12b","votes_abstain":"0","votes_against":"0","votes_for":"0","votes_withheld":null}]},"claim":"ADC Therapeutics SA shareholders approved Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company’s capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as t at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #12 : Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company’s capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as the introduction of article 4d regarding a conditional share capital based on the capital range The shareholders approved (i) amendments to article 4a paragraph 1 of the articles of association to increase the Company’s capital range from CHF 8,375,974.48 (lower limit) to CHF 12,354,128.80 (upper limit) to CHF 10,378,109.12 (lower limit) to CHF 15,567,163.68 (upper limit) (Proposal #12a), (ii) amendments to article 4b paragraph 1 of the articles of association to increase the Company’s conditional share capital for employee participation from 9,887,629 common shares (CHF 791,010.32) to 16,836,253 common shares (CHF 1,346,900.24) (Proposal #12b)","confidence":0.5,"filing_url":"https://secwatch.observer/filing/0000950103-26-008321","anchor_url":"https://secwatch.observer/filing/0000950103-26-008321#claim-0ab40d6d138120574e96ba7d805eb8674632a067","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm"},{"fact_type":"shareholder_vote","fact_key":"bb5dab9fb9bf0b4c75fc1bcaae10be6bfdeea819","cik":1771910,"ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2026-06-02T20:01:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-01","outcome":"passed","proposal_text":"Approving an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"14,253,584","subject":null,"votes_abstain":"3,817,798","votes_against":"18,904,924","votes_for":"46,624,648","votes_withheld":null}]},"claim":"ADC Therapeutics SA shareholders approved Approving an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #11 : Approving an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan The shareholders approved an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 46,624,648 18,904,924 3,817,798 14,253,584","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950103-26-008321","anchor_url":"https://secwatch.observer/filing/0000950103-26-008321#claim-bb5dab9fb9bf0b4c75fc1bcaae10be6bfdeea819","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b6e389bd969a6999f35fce9a669dbef715d317eb","cik":1771910,"ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2026-06-02T20:01:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-01","outcome":"passed","proposal_text":"Approving, on an advisory basis under U.S. law, the compensation paid to the named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"14,253,584","subject":null,"votes_abstain":"3,903,859","votes_against":"1,271,205","votes_for":"64,172,306","votes_withheld":null}]},"claim":"ADC Therapeutics SA shareholders approved Approving, on an advisory basis under U.S. law, the compensation paid to the named executive officers at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #10 : Approving, on an advisory basis under U.S. law, the compensation paid to the named executive officers The shareholders approved, on an advisory basis under U.S. law, the compensation of the Company’s named executive officers, as disclosed in “Executive Compensation” and the related compensation tables and narrative disclosure in the proxy statement. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 64,172,306 1,271,205 3,903,859 14,253,584","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950103-26-008321","anchor_url":"https://secwatch.observer/filing/0000950103-26-008321#claim-b6e389bd969a6999f35fce9a669dbef715d317eb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm"},{"fact_type":"shareholder_vote","fact_key":"882517664fa64e0e91f6f659ffe6527ecc779193","cik":1771910,"ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2026-06-02T20:01:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-01","outcome":"passed","proposal_text":"Approving, on a binding basis under Swiss law, the compensation of the board of directors and the executive committee","proposal_type":"say_on_pay","results":[{"broker_non_votes":"14,253,584","subject":"#9a","votes_abstain":"3,912,524","votes_against":"16,977,874","votes_for":"48,456,972","votes_withheld":null},{"broker_non_votes":"14,253,584","subject":"#9b","votes_abstain":"3,927,056","votes_against":"439,267","votes_for":"64,981,047","votes_withheld":null},{"broker_non_votes":"14,253,584","subject":"#9c","votes_abstain":"3,922,982","votes_against":"883,352","votes_for":"64,541,036","votes_withheld":null}]},"claim":"ADC Therapeutics SA shareholders approved Approving, on a binding basis under Swiss law, the compensation of the board of directors and the executive committee at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #9 : Approving, on a binding basis under Swiss law, the compensation of the board of directors and the executive committee The shareholders approved, on a binding basis under Swiss law, that (i) the maximum aggregate amount of compensation for the members of the board of directors for the period between the Annual Meeting and the 2027 annual general meeting of shareholders be set at $2,500,000 (Proposal #9a), (ii) the maximum aggregate amount of fixed compensation for the members of the executive committee for the year ending December 31, 2027 be set at $2,600,000 (Proposal #9b) and (iii) the maximum aggregate amount of variable compensation for the members of the executive committee for the year ending December 31, 2026 be set at $5,500,000 (Proposal #9c). The voting results were as follows: PROPOSAL FOR AGAINST ABSTAIN BROKER NON-VOTES #9a 48,456,972 16,977,874 3,912,524 14,253,584 #9b 64,981,047 439,267 3,927,056 14,253,584 #9c 64,541,036 883,352 3,922,982 14,253,584","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950103-26-008321","anchor_url":"https://secwatch.observer/filing/0000950103-26-008321#claim-882517664fa64e0e91f6f659ffe6527ecc779193","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3b2bfa4e6ad7ebd4dab119a54f61c10b4dc1b1c1","cik":1771910,"ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2026-06-02T20:01:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-01","outcome":"passed","proposal_text":"Reelecting the auditors","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"3,822,449","votes_against":"31,325","votes_for":"79,747,180","votes_withheld":null}]},"claim":"ADC Therapeutics SA shareholders approved Reelecting the auditors at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #8 : Reelecting the auditors The shareholders reelected PricewaterhouseCoopers SA as the statutory auditor and independent registered public accounting firm for the year ending December 31, 2026. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 79,747,180 31,325 3,822,449 —","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950103-26-008321","anchor_url":"https://secwatch.observer/filing/0000950103-26-008321#claim-3b2bfa4e6ad7ebd4dab119a54f61c10b4dc1b1c1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7bf4be04ddcfd74c76cc2b8f6dbe64220338e31d","cik":1771910,"ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2026-06-02T20:01:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-01","outcome":"passed","proposal_text":"Reelecting the Independent Proxy","proposal_type":"other","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"3,826,708","votes_against":"17,712","votes_for":"79,756,534","votes_withheld":null}]},"claim":"ADC Therapeutics SA shareholders approved Reelecting the Independent Proxy at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #7 : Reelecting the Independent Proxy The shareholders reelected PHC Notaires, in Lausanne, Switzerland, as the Independent Proxy for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 79,756,534 17,712 3,826,708 —","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950103-26-008321","anchor_url":"https://secwatch.observer/filing/0000950103-26-008321#claim-7bf4be04ddcfd74c76cc2b8f6dbe64220338e31d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3bffc3dad991a209463707636395918f3af29e9f","cik":1771910,"ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2026-06-02T20:01:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-01","outcome":"passed","proposal_text":"Reelecting compensation committee members","proposal_type":"other","results":[{"broker_non_votes":"14,253,584","subject":"Robert Azelby","votes_abstain":"3,822,360","votes_against":"388,421","votes_for":"65,136,589","votes_withheld":null},{"broker_non_votes":"14,253,584","subject":"Peter Hug","votes_abstain":"3,863,359","votes_against":"469,178","votes_for":"65,014,833","votes_withheld":null},{"broker_non_votes":"14,253,584","subject":"Victor Sandor","votes_abstain":"3,821,509","votes_against":"380,752","votes_for":"65,145,109","votes_withheld":null}]},"claim":"ADC Therapeutics SA shareholders approved Reelecting compensation committee members at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #6 : Reelecting compensation committee members The shareholders reelected the following members of the compensation committee for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders. The voting results were as follows: NAME FOR AGAINST ABSTAIN BROKER NON-VOTES Robert Azelby 65,136,589 388,421 3,822,360 14,253,584 Peter Hug 65,014,833 469,178 3,863,359 14,253,584 Victor Sandor 65,145,109 380,752 3,821,509 14,253,584","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950103-26-008321","anchor_url":"https://secwatch.observer/filing/0000950103-26-008321#claim-3bffc3dad991a209463707636395918f3af29e9f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d2e176a86086bd7c2c5578700fb8e92c788ca616","cik":1771910,"ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2026-06-02T20:01:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-01","outcome":"passed","proposal_text":"Reelecting directors","proposal_type":"director_election","results":[{"broker_non_votes":"14,253,584","subject":"Ron Squarer","votes_abstain":"3,821,799","votes_against":"416,194","votes_for":"65,109,377","votes_withheld":null},{"broker_non_votes":"14,253,584","subject":"Robert Azelby","votes_abstain":"3,822,809","votes_against":"429,835","votes_for":"65,094,726","votes_withheld":null},{"broker_non_votes":"14,253,587","subject":"Jean-Pierre Bizzari","votes_abstain":"3,863,025","votes_against":"1,852,731","votes_for":"63,631,611","votes_withheld":null},{"broker_non_votes":"14,253,584","subject":"Timothy Coughlin","votes_abstain":"3,821,374","votes_against":"327,049","votes_for":"65,198,947","votes_withheld":null},{"broker_non_votes":"14,253,584","subject":"Peter Hug","votes_abstain":"3,863,224","votes_against":"556,545","votes_for":"64,927,601","votes_withheld":null},{"broker_non_votes":"14,253,584","subject":"Ameet Mallik","votes_abstain":"3,826,944","votes_against":"387,036","votes_for":"65,133,390","votes_withheld":null},{"broker_non_votes":"14,253,584","subject":"Viviane Monges","votes_abstain":"3,871,625","votes_against":"556,772","votes_for":"64,918,973","votes_withheld":null},{"broker_non_votes":"14,253,584","subject":"Tyrell Rivers","votes_abstain":"3,821,374","votes_against":"729,534","votes_for":"64,796,462","votes_withheld":null},{"broker_non_votes":"14,253,584","subject":"Victor Sandor","votes_abstain":"3,822,225","votes_against":"373,932","votes_for":"65,151,213","votes_withheld":null}]},"claim":"ADC Therapeutics SA shareholders approved Reelecting directors at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #5 : Reelecting directors The shareholders reelected the following directors for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders. The voting results were as follows: NAME FOR AGAINST ABSTAIN BROKER NON-VOTES Ron Squarer 65,109,377 416,194 3,821,799 14,253,584 Robert Azelby 65,094,726 429,835 3,822,809 14,253,584 Jean-Pierre Bizzari 63,631,611 1,852,731 3,863,025 14,253,587 Timothy Coughlin 65,198,947 327,049 3,821,374 14,253,584 Peter Hug 64,927,601 556,545 3,863,224 14,253,584 Ameet Mallik 65,133,390 387,036 3,826,944 14,253,584 Viviane Monges 64,918,973 556,772 3,871,625 14,253,584 Tyrell Rivers 64,796,462 729,534 3,821,374 14,253,584 Victor Sandor 65,151,213 373,932 3,822,225 14,253,584","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950103-26-008321","anchor_url":"https://secwatch.observer/filing/0000950103-26-008321#claim-d2e176a86086bd7c2c5578700fb8e92c788ca616","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm"},{"fact_type":"shareholder_vote","fact_key":"9d6d59f0aa7cebe79b2c826ab36db11800e9500d","cik":1771910,"ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2026-06-02T20:01:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-01","outcome":"passed","proposal_text":"Approving the appropriation of the financial results","proposal_type":"other","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"3,817,497","votes_against":"8,511","votes_for":"79,774,946","votes_withheld":null}]},"claim":"ADC Therapeutics SA shareholders approved Approving the appropriation of the financial results at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #4 : Approving the appropriation of the financial results The shareholders approved that the net loss for the year ended December 31, 2025 be carried forward. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 79,774,946 8,511 3,817,497 —","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950103-26-008321","anchor_url":"https://secwatch.observer/filing/0000950103-26-008321#claim-9d6d59f0aa7cebe79b2c826ab36db11800e9500d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4bc2faeb988a3a214dc84759152632a041fb644f","cik":1771910,"ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2026-06-02T20:01:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-01","outcome":"passed","proposal_text":"Discharging the members of the board of directors and the executive committee from liability","proposal_type":"other","results":[{"broker_non_votes":"14,253,584","subject":null,"votes_abstain":"3,966,182","votes_against":"86,523","votes_for":"63,695,590","votes_withheld":null}]},"claim":"ADC Therapeutics SA shareholders approved Discharging the members of the board of directors and the executive committee from liability at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #3 : Discharging the members of the board of directors and the executive committee from liability The shareholders approved that the members of the board of directors and the executive committee be discharged from liability for the year ended December 31, 2025. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 63,695,590 86,523 3,966,182 14,253,584","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950103-26-008321","anchor_url":"https://secwatch.observer/filing/0000950103-26-008321#claim-4bc2faeb988a3a214dc84759152632a041fb644f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm"},{"fact_type":"shareholder_vote","fact_key":"110f1c90c9145b002c05b59342e411c734502562","cik":1771910,"ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2026-06-02T20:01:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-01","outcome":"passed","proposal_text":"Approving, on an advisory basis under Swiss law, the compensation report","proposal_type":"say_on_pay","results":[{"broker_non_votes":"14,253,584","subject":null,"votes_abstain":"3,815,289","votes_against":"1,242,782","votes_for":"64,289,299","votes_withheld":null}]},"claim":"ADC Therapeutics SA shareholders approved Approving, on an advisory basis under Swiss law, the compensation report at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #2 : Approving, on an advisory basis under Swiss law, the compensation report The shareholders approved, in a non-binding advisory vote, the compensation report for the year ended December 31, 2025. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 64,289,299 1,242,782 3,815,289 14,253,584","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950103-26-008321","anchor_url":"https://secwatch.observer/filing/0000950103-26-008321#claim-110f1c90c9145b002c05b59342e411c734502562","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1a1dd51b508d64e8ed72291fb4598d2ba09a6b7a","cik":1771910,"ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2026-06-02T20:01:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-01","outcome":"passed","proposal_text":"Approving the management report, annual financial statements and consolidated financial statements","proposal_type":"unknown","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"3,889,590","votes_against":"5,910","votes_for":"79,705,454","votes_withheld":null}]},"claim":"ADC Therapeutics SA shareholders approved Approving the management report, annual financial statements and consolidated financial statements at the 2026-06-01 meeting.","evidence_excerpt":"Proposal #1 : Approving the management report, annual financial statements and consolidated financial statements The shareholders approved the management report, the annual financial statements and the consolidated financial statements for the year ended December 31, 2025 and acknowledged the auditors’ report for the year ended December 31, 2025. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 79,705,454 5,910 3,889,590 —","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950103-26-008321","anchor_url":"https://secwatch.observer/filing/0000950103-26-008321#claim-1a1dd51b508d64e8ed72291fb4598d2ba09a6b7a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm"},{"fact_type":"earnings_release","fact_key":"9b53da2b938c8e270d36cb94082a84e41395ec97","cik":1771910,"ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2026-05-04T23:59:59+00:00","payload":{"eps_text":"$0.21 per basic and diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$33.0 million","period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-04","result_type":"reported_results","revenue_text":"$20.0 million"},"claim":"ADC Therapeutics SA reported the first quarter ended March 31, 2026 results: revenue $20.0 million, net income $33.0 million, EPS $0.21 per basic and diluted share.","evidence_excerpt":"Updates LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE,","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-029524","anchor_url":"https://secwatch.observer/filing/0001628280-26-029524#claim-9b53da2b938c8e270d36cb94082a84e41395ec97","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1771910/000162828026029524/0001628280-26-029524-index.htm"},{"fact_type":"material_agreement","fact_key":"243f65eda82a525b00026622e020faf97d42459d","cik":1771910,"ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2026-02-23T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment","agreement_type":"asset_purchase","counterparty":"entities managed by HealthCare Royalty Management, LLC","effective_date":"2026-02-18","item_codes_triggered":["1.01"],"value_text":null},"claim":"ADC Therapeutics SA amended Amendment with entities managed by HealthCare Royalty Management, LLC (effective 2026-02-18).","evidence_excerpt":"On February 18, 2026, ADC Therapeutics SA (the “Company”) entered into an amendment (the “Amendment”) to the Purchase and Sale Agreement, dated August 25, 2021 (the “Original Agreement” and, as amended by the Amendment, the “Amended Agreement”), among the Company and entities managed by HealthCare Royalty Management, LLC (“HCR”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950103-26-002466","anchor_url":"https://secwatch.observer/filing/0000950103-26-002466#claim-243f65eda82a525b00026622e020faf97d42459d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326002466/0000950103-26-002466-index.htm"},{"fact_type":"restructuring_charge","fact_key":"ef3a75192f24413c091a04db0d31f3aead037136","cik":1771910,"ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2025-06-12T23:59:59+00:00","payload":{"affected_area":"U.K. research and development facility","charge_text":"approximately $6 million to $7 million","effective_date":"2025-06-11","event_type":"restructuring","headcount_text":"approximately 30%","item_codes_triggered":["2.05"]},"claim":"ADC Therapeutics SA announced a restructuring with charges of approximately $6 million to $7 million affecting U.K. research and development facility (approximately 30%).","evidence_excerpt":"On June 11, 2025, the Board of Directors of the Company approved a strategic reprioritization and restructuring plan (the “Restructuring”) to focus resources on ZYNLONTA® (loncastuximab tesirine-lpyl) expansion opportunities and the advancement of its preclinical exatecan-based ADC targeting prostate-specific membrane antigen (PSMA). The Company will discontinue early development efforts for the remaining preclinical programs in solid tumors. In connection with the Restructuring, the Company plans to shut down its U.K. research and development facility and reduce its global workforce across functions by approximately 30%, which is expected to be substantially completed by September 30, 2025. The Company estimates that it will incur one-time pre-tax restructuring charges of approximately $6 million to $7 million for employee severance, benefits and related termination costs, the majority of which the Company expects to be recognized in the second quarter of 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950103-25-007282","anchor_url":"https://secwatch.observer/filing/0000950103-25-007282#claim-ef3a75192f24413c091a04db0d31f3aead037136","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010325007282/0000950103-25-007282-index.htm"},{"fact_type":"earnings_release","fact_key":"756c6260785459d16af2001b76aa894944648a2a","cik":1771910,"ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2024-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-06","result_type":"reported_results","revenue_text":null},"claim":"ADC Therapeutics SA reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"On May 6, 2024, ADC Therapeutics SA (the “Company”) issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-24-020447","anchor_url":"https://secwatch.observer/filing/0001628280-24-020447#claim-756c6260785459d16af2001b76aa894944648a2a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1771910/000162828024020447/0001628280-24-020447-index.htm"}]}